Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma

Fig. 3

Characterization and in vitro experiments of DOX-CB@lipo-pDNA-iRGD. a Measurement of intranuclear and cellular boron uptake in GL261 cells. Cells were incubated for 3 h in the presence of DOX-CB at the dose of 16 μg/mL. b Measurement of intranuclear and cellular boron uptake in GL261 cells. Cells were incubated for 3 h in the different preparations at the dose of 16 μg/mL. c Transmission electron microscopic (TEM) image of DOX-CB@lipo-pDNA (B) and DOX-CB@lipo-pDNA-iRGD. Scale bar = 100 nm. d Confocal microscopy showing the cellular distribution of DOX and DOX-CB. GL261 cells were incubated with DOX or DOX-CB at the equivalent DOX concentration of 3.5 μM for 3 h. e Confocal microscopy showing the cellular distribution of different formations with or without proteasome inhibitor

Back to article page